Phio Pharmaceuticals Corp stock is traded at $0.7172, with a volume of 65,486. It is down -4.65% in the last 24 hours and down -17.67% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Previous Close:
$0.7522
Open:
$0.75
24h Volume:
65,486
Relative Volume:
0.81
Market Cap:
$8.57M
Revenue:
$153.00K
Net Income/Loss:
-$10.93M
P/E Ratio:
-
EPS:
-$1.44
Net Cash Flow:
-$10.72M
1W Performance:
-11.87%
1M Performance:
-17.67%
6M Performance:
-32.97%
1Y Performance:
-45.67%
1-Day Range:
$0.7021$0.75
1-Week Range:
$0.7021$0.8598
52-Week Range:
$0.7021$1.88
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals CorpSector
HealthcareIndustry
BiotechnologyPhone
(508) 767-3861Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS